{"id":"human-dopaminergic-progenitor-cells","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Human Dopaminergic Progenitor Cells are a type of cell therapy that aims to treat neurodegenerative disorders by replenishing dopamine-producing neurons.","oneSentence":"Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:01:59.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT07102342","phase":"PHASE1","title":"This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.","status":"RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2026-01-12","conditions":"Parkinson Disease","enrollment":5},{"nctId":"NCT06944522","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease","status":"RECRUITING","sponsor":"BlueRock Therapeutics","startDate":"2025-06-17","conditions":"Parkinsons Disease (PD)","enrollment":102},{"nctId":"NCT06778265","phase":"PHASE1","title":"An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai UniXell Biotechnology Co., Ltd","startDate":"2025-03-01","conditions":"Parkinson Disease, Idiopathic","enrollment":12},{"nctId":"NCT07166757","phase":"PHASE1, PHASE2","title":"Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease","status":"RECRUITING","sponsor":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","startDate":"2025-09-22","conditions":"Parkinson Disease (PD)","enrollment":90},{"nctId":"NCT07289477","phase":"PHASE1","title":"A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy","status":"NOT_YET_RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2025-12","conditions":"Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","enrollment":9},{"nctId":"NCT05635409","phase":"PHASE1","title":"A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2022-11-30","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT06422208","phase":"PHASE1","title":"Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Penelope J. Hallett, Ph.D.","startDate":"2024-08-07","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT07080775","phase":"PHASE1","title":"The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease","status":"RECRUITING","sponsor":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","startDate":"2025-08-05","conditions":"Parkinson's Disease","enrollment":12},{"nctId":"NCT06978920","phase":"PHASE1","title":"A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease","status":"RECRUITING","sponsor":"Nuwacell Biotechnologies Co., Ltd.","startDate":"2025-06-06","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT07028632","phase":"PHASE2","title":"The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2025-06-30","conditions":"Parkinson Disease (PD)","enrollment":30},{"nctId":"NCT06482268","phase":"PHASE1","title":"Transplantation of Human iPS Cell-derived Dopaminergic Progenitors (CT1-DAP001) for Parkinson's Disease (Phase I/II)","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-06-01","conditions":"PD - Parkinson's Disease","enrollment":7},{"nctId":"NCT06608355","phase":"PHASE1","title":"The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease","status":"RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2024-08-23","conditions":"Early-onset Parkinson's Disease","enrollment":6},{"nctId":"NCT04802733","phase":"PHASE1","title":"Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"BlueRock Therapeutics","startDate":"2021-05-03","conditions":"Advanced Parkinson's Disease","enrollment":12},{"nctId":"NCT06167681","phase":"PHASE1, PHASE2","title":"The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease","status":"RECRUITING","sponsor":"iRegene Therapeutics Co., Ltd.","startDate":"2024-01-17","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT06145711","phase":"NA","title":"A Clinical Trial of Parkinson's Disease Treatment by HiPSCs Derived Dopaminergic Neural Precursor Cells","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2023-11-23","conditions":"Parkinson's Disease","enrollment":3},{"nctId":"NCT05897957","phase":"","title":"Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01","status":"ENROLLING_BY_INVITATION","sponsor":"BlueRock Therapeutics","startDate":"2023-05-16","conditions":"Parkinson Disease","enrollment":12},{"nctId":"NCT01534624","phase":"","title":"Stem Cell Study of Genetics and Drug Addiction","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2012-02-07","conditions":"Induced Pluripotent Stem Cells","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NouvNeu001"],"phase":"phase_2","status":"active","brandName":"Human Dopaminergic Progenitor Cells","genericName":"Human Dopaminergic Progenitor Cells","companyName":"iRegene Therapeutics Co., Ltd.","companyId":"iregene-therapeutics-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain. Used for Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}